For patients with early-stage HER2-positive breast cancer receiving adjuvant therapy, intrinsic resistance refers to recurrence or metastasis developing within 12 months of anti-HER2 treatment, while acquired resistance refers to recurrence or metastasis developing 12 months after the end of anti-HER2 adjuvant therapy. Here, ERBB2 is linked to breast carcinoma.